PRPH Quote, Financials, Valuation and Earnings

Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 7.87%. ProPhase Labs's return on equity of -59.59% beat Fonar's return on equity of 4.95%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4725.18%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are smaller than Fonar quarterly revenues of $25M. ProPhase Labs's net income of -$6.6M is lower than Fonar's net income of $2M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 10.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.86x versus 0.78x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

OncoCyte has a net margin of -209.38% compared to ProPhase Labs's net margin of -2255.11%. ProPhase Labs's return on equity of -59.59% beat OncoCyte's return on equity of -581.11%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4725.18%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 56.07%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are larger than OncoCyte quarterly revenues of $1.5M. ProPhase Labs's net income of -$6.6M is higher than OncoCyte's net income of -$33.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.86x versus 19.66x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 4.31%. ProPhase Labs's return on equity of -59.59% beat Veracyte's return on equity of 2.14%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4725.18%. On the other hand Veracyte has an analysts' consensus of $41.50 which suggests that it could grow by 36.84%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are smaller than Veracyte quarterly revenues of $118.6M. ProPhase Labs's net income of -$6.6M is lower than Veracyte's net income of $5.1M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is 102.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.86x versus 5.38x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -56.4%. ProPhase Labs's return on equity of -59.59% beat XWELL's return on equity of -71.82%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4725.18%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 751.58%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are smaller than XWELL quarterly revenues of $8.4M. ProPhase Labs's net income of -$6.6M is lower than XWELL's net income of -$4.8M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.86x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.